Clinical trials: Untreated
Advanced Pancreatic Ductal Adenocarcinoma
Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma
Icaritin is a drug that has been approved by the National Medical Products Administration (NMPA) based on a multicenter, randomized, double-blind, parallel-controlled Phase III clinical trial - SNG1705 ICR-1.
- Trial name
- NCT06825546
- Testing
- Icaritin, AG chemotherapy
- Where
- 6 sites in China
- Volunteers
- 70 people
- Sponsor
- Sir Run Run Shaw Hospital
Prostatic Neoplasm
A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma
One current hypothesis as to what limits duration of initial hormone response is the rapid emergence of hormone resistant prostate carcinoma cells.
- Trial name
- NCT00001266
- Testing
- Suramin
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Acute Leukemias of Ambiguous Lineage, Bacterial Infection
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
This randomized phase III trial studies how well levofloxacin works in preventing infection in young patients with acute leukemia receiving chemotherapy or undergoing stem cell transplant.
- Conditions
- Acute Leukemias of Ambiguous Lineage, Bacterial Infection, Diarrhea, Fungal Infection
- Trial name
- NCT01371656
- Testing
- levofloxacin
- Where
- 84 sites in United States, Canada
- Volunteers
- 624 people
- Sponsor
- Children's Oncology Group
Primary Mediastinal Diffuse Large B-cell Lymphoma
Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL
The goal of this clinical study is to evaluate the efficacy and safety of sintilimab combined with rituximab followed by R-CHOP regimen in treatment-naïve patients with primary mediastinal diffuse large B-cell lymphoma.
- Trial name
- Si-Ri (NCT06742502)
- Testing
- Sintlimab+Rituximab follwed by R-CHOP(Cyclophosphamide, doxorubicin, vincristine, prednisone)
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Ann Arbor Stage II Follicular Lymphoma, Grade 1 Follicular Lymphoma
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
This is a single center, open label, single arm phase II clinical trial. The objective of this study is to assess the feasibility and efficacy of zanubrutinib combined with venetoclax and Rituximab in patients with previously…
- Conditions
- Ann Arbor Stage II Follicular Lymphoma, Grade 1 Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma
- Trial name
- NCT06471738
- Testing
- Zanubrutinib, Rituximab, Venetoclax
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Metastatic Pancreatic Ductal Adenocarcinoma
Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
There will be two phases to this study. The lead-in phase will evaluate the safety, pharmacokinetics, and define the maximum tolerated dose (MTD) of momelotinib (MMB) combined with nab-paclitaxel and gemcitabine (nab-P + G) in…
- Trial name
- NCT02101021
- Testing
- Momelotinib, Nab-paclitaxel, Gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Leukemia
Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as laromustine, daunorubicin, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00840684
- Testing
- amsacrine, busulfan, cytarabine
- Where
- France
- Volunteers
- 135 people
- Sponsor
- Institut Paoli-Calmettes
AML (Acute Myeloid Leukemia)
VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial
This is a multicenter, prospective, single-arm clinical study designed to evaluate the efficacy and safety of the VA-CIG regimen (venetoclax combined with azacitidine, idarubicin, low-dose cytarabine and granulocyte…
- Trial name
- NCT07514832
- Testing
- Venetoclax, Azacitidine, Cytarabine, Idarubicin, G-CSF
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Beijing 302 Hospital
HIV
Epidemiological Study of HIV in the South African National Defense Force
This project, called PHIDISA I, will screen uniformed personnel of the South African National Defense Force (SANDF) and their registered family members for HIV, hepatitis B and C, gonorrhea, syphilis, and chlamydia to determine…
- Trial name
- NCT00341887
- Where
- 5 sites in South Africa
- Volunteers
- 8,676 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors
A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations
The main purpose of this study is to evaluate the safety and efficacy of Apatinib in combination with Gefitinib as compared to placebo in combination with Gefitinib in participants with stage ⅢB-IV Non-squamous non-small-cell…
- Trial name
- NCT02824458
- Testing
- Apatinib, Gefitinib
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Sun Yat-sen University
Follicular Lymphoma
A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide
Evaluate the efficacy and safety of orelabrutinib, tafasitamab, and lenalidomide in the first-line treatment of patients with follicular lymphoma.
- Trial name
- CUREMZL002 (NCT07585747)
- Testing
- Orelabrutinib, Tafasitamab, Lenalidomide
- Where
- 5 sites in China
- Volunteers
- 27 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Squamous Cell Lung Cancer
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)
To evaluate the overall survival (OS) of patients with advanced squamous cell lung cancer receiving the combination of gemcitabine/carboplatin either with or without Iniparib.
- Trial name
- ECLIPSE (NCT01082549)
- Testing
- gemcitabine/carboplatin, gemcitabine/carboplatin plus Iniparib
- Where
- 142 sites in United States, Belgium and 12 more
- Volunteers
- 780 people
- Sponsor
- Sanofi
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
This phase I/II trial is studying the side effects and best way to give nilotinib when given alone or sequentially after imatinib mesylate after donor stem cell transplant in treating patients with acute lymphoblastic leukemia or…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT00702403
- Testing
- nilotinib, imatinib mesylate, pharmacological study
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
Metastatic Pancreatic Adenocarcinoma
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
The question being asked in this study is: Will patients with advanced pancreatic cancer live significantly longer if they are treated with a combination of Gemcitabine and ON 01910.Na than if they are treated with Gemcitabine…
- Trial name
- ONTRAC (NCT01360853)
- Testing
- ON 01910.Na, Gemcitabine
- Where
- 46 sites in United States, Hungary and 3 more
- Volunteers
- 160 people
- Sponsor
- Traws Pharma, Inc.
CLL, B-cell
Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients
This is a non interventional study to evaluate the efficacy and safety of Chlorambucil plus Rituximab as firstline therapy in elderly and/or unfit patients affected by B-cell Chronic Lymphocytic Leukemia (B-CLL).
- Conditions
- CLL, B-cell, Small Lymphocytic Lymphoma, Untreated B-CLL
- Trial name
- NCT01862445
- Where
- 20 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
The goal of this clinical trial is to study the addition of Acalabrutinib to standard R-miniCHOP in older adults with DLBCL. The main question it aims to answer is whether progression free survival kann be prolonged with the…
- Trial name
- ARCHED (NCT05820841)
- Testing
- R-miniCHOP + Acalabrutinib, R-miniCHOP
- Where
- 17 sites in Germany
- Volunteers
- 330 people
- Sponsor
- Universität des Saarlandes
Brain and Central Nervous System Tumors
Biomarkers in Blood Samples From Young Patients With Newly Diagnosed Brain Tumors Undergoing Standard Radiation Therapy and Chemotherapy
RATIONALE: Studying samples of blood in the laboratory from patients receiving radiation therapy and chemotherapy may help doctors learn more about the effects of this treatment on cells.
- Trial name
- NCT01233479
- Testing
- systemic chemotherapy, laboratory biomarker analysis, therapeutic surgical procedure
- Where
- 11 sites in United States
- Sponsor
- Pediatric Brain Tumor Consortium
Lymphoma, T-Cell, Peripheral
Alemtuzumab and CHOP in T-cell Lymphoma
The purpose of this study is to determine efficacy and safety of the monoclonal antibody MabCampath® (alemtuzumab) combined with chemotherapy in the treatment of T-cell lymphoma.
- Trial name
- ACT-1 (NCT00646854)
- Testing
- CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab, CHOP14 chemotherapy (see specification under Arm B) plus G-CSF
- Where
- 59 sites in Austria, Belgium and 9 more
- Volunteers
- 136 people
- Sponsor
- Aarhus University Hospital
Non-Small Cell Lung Cancer
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
This study will assess the efficacy and safety of Avastin combined with first li ne paclitaxel-carboplatin (cohort 1) or second line Tarceva (cohort 2) in patien ts with non-squamous non-small cell lung cancer with asymptomatic…
- Trial name
- NCT00800202
- Testing
- bevacizumab [Avastin], carboplatin, erlotinib [Tarceva]
- Where
- 25 sites in France
- Volunteers
- 91 people
- Sponsor
- Hoffmann-La Roche
Leukemia
Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
RATIONALE: Hormone therapy may stop the growth of cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00003437
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- United Kingdom
- Volunteers
- 1,800 people
- Sponsor
- Medical Research Council
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.